Who are Dexmedetomidine, midazolam; fentanyl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): dexmedetomidine (IN), Methadone-dexmedetomidine-ketamine combination, Group D : Dexmedetomidine + propofol group, Dexmedetomidine (DEX), Normal saline, Lidocaine, dexmetomidine, Venlafaxine XR + Mirtazapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexmedetomidine-midazolam-fentanyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dexmedetomidine, midazolam; fentanyl — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexmedetomidine, midazolam; fentanyl (Dexmedetomidine, midazolam; fentanyl) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sedative-hypnotic. Area: Oncology.

phase 2 Sedative-hypnotic Alpha-2 adrenergic receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Dexmedetomidine, midazolam; fentanyl (Dexmedetomidine, midazolam; fentanyl) — Hospira, now a wholly owned subsidiary of Pfizer. Alpha-2 adrenergic receptor agonist

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dexmedetomidine, midazolam; fentanyl TARGET	Dexmedetomidine, midazolam; fentanyl	Hospira, now a wholly owned subsidiary of Pfizer	phase 2	Sedative-hypnotic	Alpha-2 adrenergic receptor
dexmedetomidine (IN)	dexmedetomidine (IN)	Azienda Ospedaliera di Padova	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Methadone-dexmedetomidine-ketamine combination	Methadone-dexmedetomidine-ketamine combination	University of Missouri-Columbia	marketed	Anesthetic combination (opioid + alpha-2 agonist + NMDA antagonist)	Mu opioid receptor, alpha-2 adrenergic receptor, NMDA receptor
Group D : Dexmedetomidine + propofol group	Group D : Dexmedetomidine + propofol group	Seoul National University Hospital	marketed	Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist)	Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)
Dexmedetomidine (DEX)	Dexmedetomidine (DEX)	Ain Shams University	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Normal saline, Lidocaine, dexmetomidine	Normal saline, Lidocaine, dexmetomidine	Kasr El Aini Hospital	marketed	Local anesthetic combination with sedative-analgesic agent	Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Venlafaxine XR + Mirtazapine	Venlafaxine XR + Mirtazapine	National Institute of Mental Health (NIMH)	marketed	Antidepressant combination (SNRI + NaSSA)	Serotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sedative-hypnotic class)

Hospira, now a wholly owned subsidiary of Pfizer · 1 drug in this class
Life Extension Foundation Inc. · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
University Hospital, Brest · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexmedetomidine, midazolam; fentanyl — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-midazolam-fentanyl. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab